hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06280664, orgStudyIdInfo id: IRB20-1151, briefTitle: Efficacy Of Hiatal Closure For GERD, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-10-02, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, descriptionModule briefSummary: The purpose of this protocol is to study the efficacy of hiatal closure for early GERD disease. The study team hypothesizes that hiatal closure for early GERD disease is an efficacious treatment of GERD., conditionsModule conditions: Gastro Esophageal Reflux, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, outcomesModule primaryOutcomes measure: Concentration of pH testing, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: The University of Chicago, status: RECRUITING, city: Chicago, state: Illinois, zip: 60637, country: United States, contacts name: Carlisa Dixon, role: CONTACT, phone: 773-834-4337, email: cdixon520@bsd.uchicago.edu, contacts name: Leila Yazdanbakhsh, role: CONTACT, phone: 773-834-5087, email: leila.yazdanbakhsh@bsd.uchicago.edu, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06280651, orgStudyIdInfo id: RGP 2/348/44, secondaryIdInfos id: RGP 2/348/44, type: OTHER_GRANT, domain: kING kHALID UNIVERSITY, briefTitle: Dietary Impacts on Oral Health in Autistic Children: A Cross-Sectional Analysis, acronym: OHIDPAP-CS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-05-15, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: King Khalid University, class: OTHER, descriptionModule briefSummary: The study aims to explore how dietary habits affect oral health in children with autism. By examining a cross-section of the autistic paediatric population, the research seeks to identify patterns or specific dietary preferences that may contribute to or mitigate oral health issues. This observational study does not intervene in participants' diets but observes existing habits and their oral health outcomes, aiming to provide insights that could guide better dietary recommendations and oral health practices for children with autism., conditionsModule conditions: Dental Caries in Children, conditions: Autistic Disorder, conditions: Dietary Habits, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: dietary preferences and their implications for oral health in children with Autism Spectrum Disorder, outcomesModule primaryOutcomes measure: Assess the association between oral hygiene and periodontal disease severity to identify potential implications of dietary preferences for oral health status, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06280612, orgStudyIdInfo id: RCS10042023, briefTitle: The Effect of Live Cat and Simulation Cat Therapies on Oncology Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-07-15, completionDateStruct date: 2023-09-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Karadeniz Technical University, class: OTHER, descriptionModule briefSummary: It is known that animals are good for humans physiologically and psychologically. Therefore, in this study, the effects of live cat and robotic cat therapies on the symptoms and happiness levels of oncology patients after chemotherapy were examined., conditionsModule conditions: Therapy-Associated Cancer, conditions: Cancer Patient, conditions: Happiness, conditions: Symptoms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The sample number of the research was calculated in the G\*Power 3.1.9.6 program. While α=0.05 was the error amount, 0.628 was the effect size, and 0.90 (90%) was the targeted test power, it was calculated as 36 patients for three groups (living cat group, robotic cat group, control group). Since there was no previous study on the subject, a study examining happiness levels in a different sample group was used as a reference. Considering situations such as wanting to leave the study or death during the research, each group was increased by 25%, and a total of 45 patients, 15 patients for each group, were included in the study., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Since the possibility of patients being affected by each other was minimal, the study was continued with only one of the live cat groups, the simulation cat group, and the control group. For example, only the live cat group and those who received chemotherapy treatment were studied before Monday afternoon., whoMasked: PARTICIPANT, enrollmentInfo count: 45, type: ACTUAL, armsInterventionsModule interventions name: Pet therapy, outcomesModule primaryOutcomes measure: Edmonton Symptom Diagnostic Scale, primaryOutcomes measure: Oxford Happiness Scale Short Form, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gümüşhane University, city: Gümüşhane, zip: 29600, country: Turkey, geoPoint lat: 40.46001, lon: 39.47176, hasResults: False
protocolSection identificationModule nctId: NCT06280599, orgStudyIdInfo id: SON KMU, briefTitle: Transitional Care Model for Patients With Stroke, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-04-29, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Kaohsiung Medical University, class: OTHER, descriptionModule briefSummary: Patients with stroke benefitted from superior improvements in physical function, particularly when performing activities of daily living, fewer visits to the emergency room, less depression symptoms, and improved health-related quality of life thanks to transitional model care. Despite widespread implementation of transitional care for stroke patients, intervention effectiveness remains inconclusive, and another concern with transitional care for patients is the scarcity of effects on specific findings., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The patients were divided into two groups: intervention (n=40) and contrast (n=40). Both groups received post-stroke usual care. The intervention group received an 8-week transitional care model for stroke patients, which included comprehensive discharge planning and home follow-up, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Transitional care model, outcomesModule primaryOutcomes measure: Self-efficacy, primaryOutcomes measure: Activities of daily living, secondaryOutcomes measure: Instrumental activities of daily living, secondaryOutcomes measure: Depression symptoms, secondaryOutcomes measure: Quality of life in stroke patients, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: RSUD Prof. Dr. W Z Johannes Kupang, status: RECRUITING, city: Kupang, zip: 308, country: Indonesia, contacts name: Sakti Oktaria Batubara, role: CONTACT, email: oktariabatubara@gmail.com, contacts role: CONTACT, phoneExt: Saragih, email: itadaryanti05@gmail.com, contacts name: Ita Daryanti Saragih, Doctoral, role: SUB_INVESTIGATOR, geoPoint lat: -10.17083, lon: 123.60694, hasResults: False
protocolSection identificationModule nctId: NCT06280573, orgStudyIdInfo id: MS1, briefTitle: COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS), acronym: COBRAMS, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Comenius University, class: OTHER, descriptionModule briefSummary: The goal of this interventional study is to test the effect of the anti-inflammatory and neuroprotective effects of this supplementary training program that includes breathing exercises, cold exposure, and meditation in patients diagnosed with multiple sclerosis.Researchers will compare the effect to control groups of MS patients without intervention., conditionsModule conditions: Multiple Sclerosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Wim Hoff method, outcomesModule primaryOutcomes measure: concentration of pro-inflammatory cytokines, primaryOutcomes measure: concentration of markers of oxidative stress, primaryOutcomes measure: concentration of NfL, primaryOutcomes measure: concentration of GFAP, primaryOutcomes measure: concentration of ecDNA, secondaryOutcomes measure: Expanded Disability Status Scale, secondaryOutcomes measure: Timed 25-Foot Walk, secondaryOutcomes measure: Nine-Hole Peg Test, secondaryOutcomes measure: Symbol Digit Modalities Test, secondaryOutcomes measure: Fatigue Scale for Motor and Cognitive Functions, secondaryOutcomes measure: General Anxiety Disorder-7, secondaryOutcomes measure: Patient Health Questionnaire-9, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Derer's University Hospital, city: Bratislava, zip: 83305, country: Slovakia, geoPoint lat: 48.14816, lon: 17.10674, hasResults: False
protocolSection identificationModule nctId: NCT06280547, orgStudyIdInfo id: CUP 13-2, secondaryIdInfos id: Cairo university, type: OTHER, domain: Cairo University, briefTitle: The Effect of Oral Health Education on Knowledge, Attitude, Practice and Dental Caries Among Egyptian School Children, acronym: KAP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2024-03-02, completionDateStruct date: 2024-04-02, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Aim of the study Assessing the effect of an oral health education program on knowledge, attitude, practice, and dental caries among a group of school children in a governmental school in Fayoum, Egypt., conditionsModule conditions: Dental Caries in Children, conditions: Knowledge, Attitudes, Practice, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 115, type: ESTIMATED, armsInterventionsModule interventions name: Oral health education, outcomesModule primaryOutcomes measure: Oral health related attitude, secondaryOutcomes measure: Change in oral health related Knowledge, attitude and practice, otherOutcomes measure: Caries experience, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 15 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06280534, orgStudyIdInfo id: XT1061-2022-01, briefTitle: Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects, acronym: XT1061, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-18, primaryCompletionDateStruct date: 2024-02-29, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Xi'an Xintong Pharmaceutical Research Co.,Ltd., class: OTHER, descriptionModule briefSummary: A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects., conditionsModule conditions: Chronic Hepatitis b, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 128, type: ESTIMATED, armsInterventionsModule interventions name: Test drug XT1061 capsules and placebo,Single dose group, interventions name: Test drug XT1061 capsules and placebo，Multiple dosing group, interventions name: Test drug XT1061 capsules and placebo，Food Impact Group, outcomesModule primaryOutcomes measure: Treatment-related adverse events, primaryOutcomes measure: Cmax, primaryOutcomes measure: Tmax, primaryOutcomes measure: t1/2, primaryOutcomes measure: AUC, primaryOutcomes measure: CL/F, primaryOutcomes measure: Vz/F, primaryOutcomes measure: CLr/F, secondaryOutcomes measure: Ae0-72 h, secondaryOutcomes measure: Fe0-72 h, secondaryOutcomes measure: bioavailability, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Hospital of Jilin University, status: RECRUITING, city: Jilin, state: Changchun, country: China, contacts name: Ding Yanhua, master, role: CONTACT, phone: 18743062721, email: 1023307193@qq.com, geoPoint lat: 43.85083, lon: 126.56028, hasResults: False
protocolSection identificationModule nctId: NCT06280508, orgStudyIdInfo id: SYSKY-2024-082-01, briefTitle: Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2027-03-31, completionDateStruct date: 2028-03-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer., conditionsModule conditions: Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab, Apatinib, Gemcitabine, cisplatin, outcomesModule primaryOutcomes measure: 1-year EFS rate, secondaryOutcomes measure: R0 Resection rate, secondaryOutcomes measure: EFS, secondaryOutcomes measure: RFS, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, status: RECRUITING, city: Guangzhou, state: China/Guangdong, country: China, contacts name: Yajin Chen, role: CONTACT, phone: 13719006202, email: cyj0509@126.com, contacts name: Changzhen Shang, role: CONTACT, phone: 13711279678, email: shangchangzhen@139.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06280495, orgStudyIdInfo id: INTENSIFY-CRC, briefTitle: Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in the liver, increase T lymphocyte infiltration, and consequently improve the postoperative prognosis for patients with surgically resectable colorectal cancer liver metastases (RAS/BRAF wild-type, pMMR/MSS) compared to FOLFOX alone., conditionsModule conditions: Colorectal Cancer, conditions: Liver Metastases, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a prospective, randomized, multicenter clinical trial. Stratified randomization based on liver metastasis characteristics, including timing, number, and size, will be conducted in eligible patients., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: Oxaliplatin, interventions name: Fluorouracil, interventions name: Serplulimab, interventions name: Bevacizumab, outcomesModule primaryOutcomes measure: 3-year Progression-Free Survival Rate, secondaryOutcomes measure: Median Overall Survival, secondaryOutcomes measure: Major Pathological Response (MPR), secondaryOutcomes measure: Pathologic complete response (pCR), secondaryOutcomes measure: Pathological Partial Response, secondaryOutcomes measure: Disease Free Survival, secondaryOutcomes measure: Treatment-related adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen University Cancer Center, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510060, country: China, contacts name: Yu-hong Li, MD, Ph D, role: CONTACT, email: liyh@sysucc.org.cn, contacts name: Yu-hong Li, MD, Ph D, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06280482, orgStudyIdInfo id: HSC-MS-23-0332, briefTitle: Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-06, primaryCompletionDateStruct date: 2025-07-25, completionDateStruct date: 2025-07-25, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: The University of Texas Health Science Center, Houston, class: OTHER, descriptionModule briefSummary: The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients., conditionsModule conditions: Smooth Muscle Dysfunction Syndrome (SMDS), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 5, type: ESTIMATED, armsInterventionsModule interventions name: Nicotinamide riboside (NR), outcomesModule primaryOutcomes measure: Change in Fluoro-18-Deoxyglucose (18F-FDG ) uptake in aortic wall as measured by positron emission tomography (PET)/computerized tomography (CT) imaging, secondaryOutcomes measure: Change in Levels of Nicotinamide adenine dinucleotide (NAD+) in whole blood as measured by high-performance liquid chromatography (HPLC), secondaryOutcomes measure: Change in Levels of NR in whole blood as measured by high-performance liquid chromatography (HPLC), secondaryOutcomes measure: Change in aortic measurements as assessed by echocardiography, secondaryOutcomes measure: Safety as assessed by number of participants that show drug toxicity as shown in bloodwork, secondaryOutcomes measure: Safety as assessed by number of participants that show drug toxicity as shown in bloodwork, secondaryOutcomes measure: Tolerability as assessed by the number of patients who complete study, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The University of Texas Health Science Center at Houston, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: David Murdock, MD, role: CONTACT, phone: 713-500-6735, email: David.R.Murdock@uth.tmc.edu, contacts name: Dianna Milewicz, MD, PhD, role: CONTACT, phone: (713) 500-6725, email: Dianna.M.Milewicz@uth.tmc.edu, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06280469, orgStudyIdInfo id: KY20232298-C-1, briefTitle: Single-operator Versus Double-operator in Single-Balloon Enteroscopy, acronym: SBE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Shuhui Liang, class: OTHER, descriptionModule briefSummary: Compared with two-person in single-balloon enteroscopy, one-person single-balloon enteroscopy has the advantages of better observation and treatment of lesions, shorter examination time, saving resources in the endoscopy room, and reducing the postoperative discomfort of the examined person, etc. However, there is no comparative study of one-person and two-person in single-balloon enteroscopy., conditionsModule conditions: Single-balloon Enteroscopy, conditions: Operation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Single-Balloon Enteroscopy, outcomesModule primaryOutcomes measure: Maximum insertion depth, secondaryOutcomes measure: Total enteroscopy rate, secondaryOutcomes measure: Positive findings, secondaryOutcomes measure: Advent events, secondaryOutcomes measure: procedural time, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xijing Hospital of Digestive Diseases, status: RECRUITING, city: Xi'an, country: China, contacts name: Shuhui Liang, role: CONTACT, phone: +862084771536, email: liangsh@fmmu.edu.cn, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False